oxacillin (pathocil) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oxacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Oxacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Oxacillin results from the inhibition of cell wall synthesis and is mediated through Oxacillin binding to penicillin binding proteins (PBPs). Oxacillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Oxacillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Oxacillin interferes with an autolysin inhibitor. Oxacillin is used in the treatment of resistant staphylococci infections. Oxacillin sodium was marketed under the trade name Bactocill.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$11.9096 - $20.7058
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2s,5r,6r)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | (5-methyl-3-phenyl-4-isoxazolyl)penicillin | 5-methyl-3-phenyl-4-isoxazolyl-penicillin | 6beta-(5-methyl-3-phenylisoxazol-4-yl)penicillanic acid | bactocill | cryptocillin | oxacilina | oxacillin | oxacilline | oxacillin sodium | oxacillin sodium hydrate | oxacillinum | oxazocillin | oxazocilline | p-12 | prostaphlin | so 16423 | sq-16423

Organizations (32)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Staphylococcal Infections (approved 1971)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Bacteremia (Phase 3)

Bacterial Infections (Phase 3)

Community-Acquired Infections (Phase 4)

Dermatology (Phase 4)

Endocarditis (Phase 4)

Gram-Positive Bacterial Infections (Phase 3)

Kidney Failure, Chronic (Phase 4)

Osteomyelitis (Phase 3)

Staphylococcal Infections (Phase 2)

Staphylococcus aureus (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue